Affordable, made-in-India HPV test kits rolled out to fight cervical cancer
HOW THE INDIGENOUS HPV KITS WORKThe newly validated kits use a chip-based real-time PCR (RT-PCR) technique, which is known for its accuracy and speed.These kits are designed to detect eight high-risk HPV genotypes, which are responsible for over 96% of cervical cancer cases globally.The evaluation of these kits was carried out by a team of experts at All India Institute of Medical Sciences (AIIMS) New Delhi, in collaboration with National Institute of Cancer Prevention and Research (NICPR) Noida, and National Institute for Research in Reproductive and Child Health (NIRRCH) Mumbai, along with support from the WHO International Agency for Research on Cancer (IARC). "The key feature of these kits is the inclusion of only the seven-eight most common cancer-causing types that will allow a very efficient and cost-effective screening programme which will be most suitable for India," Dr. Neerja Bhatla, former head of the department of Obstetrics and Gynaecology at AIIMS, Delhi and chief coordinator of the programme, told PTI.advertisementWhat sets these tests apart is their ability to be used as point-of-care tools, meaning they can deliver results quickly and can be used even in resource-limited or rural healthcare settings. This is particularly important in India, where access to diagnostic labs can be a major barrier."Given the enhancement of RTPCR-based diagnostic facilities across the nation in the post-COVID era, the introduction of sensitive RTPCR-based HPV testing kits might prove to be cost effective screening method over classical HPV DNA and Pap smear for deployment in the national cancer screening programme," Dr Bhatla said.A PUBLIC HEALTH THREATHPV (human papillomavirus) is a common viral infection that spreads through skin-to-skin contact, quite often via sexual contact. The virus is so common that nearly all sexually active individuals will contract it at some point in their lives, according to the World Health Organisation (WHO). While most HPV are harmless, some virus variants pose severe health problems leading to various forms of cancer, including cervical cancer.Cervical cancer is a serious public health issue in India, which accounts for nearly one in every four cervical cancer cases globally. Each year, over 1.23 lakh women are newly diagnosed, and nearly 77,000 women lose their lives to the disease.
Cervical cancer is a serious public health issue in India, which accounts for nearly one in every four cervical cancercases globally. ()
What makes this disease more concerning is that cervical cancer is preventable. While not all cervical cancer cases are because of HPV infection, most cases are caused by the virus. Therefore, early and regular screening for HPV can help catch the disease before it becomes deadly.THe WHO recently recommended that all countries adopt HPV testing as the primary screening method. According to the health agency's global strategy, women should undergo two HPV tests in their lifetime, once at the age of 35 and again at 45.The target is to screen 70% of eligible women by 2030, which would drastically reduce cervical cancer deaths.'A STEP FORWARD IN PREVENTIVE CARE'Union Minister Dr Jitendra Singh underlined the growing importance of preventive healthcare and India's efforts to become a global leader in this space.At the event where the two made-in-India HPV testing kits designed for quick screening of cervical cancer were launched, Jitendra Singh said it was the right time to acknowledge India's growing success in scientific innovation, especially in the healthcare sector.advertisementHe cited the development of the world's first DNA vaccine for Covid-19, which was also made in India back in 2021, as a major achievement that brought international recognition and helped shift global perceptions.
Union Minister Dr Jitendra Singh underlined the growing importance of preventive healthcare at the launch of two made-in-India HPV testing kits. (Photo: Department of Biotechnology)
"India was once seen as a country that neither focused on preventive nor curative healthcare. That perception is changing," he said, also mentioning Nafithromycin, the country's first indigenous antibiotic, and a gene therapy trial for haemophilia, the results of which were published in the New England Journal of Medicine.He credited these milestones to the combined efforts of public institutions and private companies, describing it as a "whole-of-science and whole-of-government" approach.The current methods of screening for cervical cancer include Visual Inspection with Acetic Acid (VIA), Papanicolaou test (Pap test or Pap smear) and HPV DNA testing. These tests are costly and time-consuming, and not always sensitive enough, said Singh.The new HPV test kits are faster, more affordable, and suitable for use in remote areas.Trending Reel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
New health guidelines for high blood pressure: Don't ignore even mild high BP
High blood pressure, often called the 'silent killer,' is no longer just a Western health problem. In India, nearly 20 crore individuals are estimated to have hypertension, and the numbers are rising sharply in cities and smaller towns alike. It is now a leading cause of heart attacks, strokes, kidney failure, and even dementia.A new joint guideline from the American Heart Association (AHA) and the American College of Cardiology (ACC) is calling for earlier action through prevention, early treatment, and more personalised these guidelines are US-based, they carry lessons that are just as urgent for India. It says that high blood pressure should be treated earlier, not just with medicines, but also with healthy lifestyle changes. It stresses the need to carefully monitor blood pressure before, during and after pregnancy, and recommends using a new tool called the PREVENT risk calculator to check a person's chances of heart disease. Moderating alcohol intake is also one of the key ways to reduce high blood pressure, as per the new EARLY ACTION MATTERSHigh blood pressure doesn't always show symptoms until it has already caused serious damage. It is the pressure of the blood flow against the arteries is consistently can silently weaken blood vessels, strain the heart, and even harm the brain. New research highlighted in the guideline shows that hypertension can accelerate memory problems and increase the risk of dementia, a concern for India as life expectancy rises and cases of Alzheimer's disease grow.'High blood pressure is the most common and most modifiable risk factor for heart disease,' said Dr. Daniel W. Jones, chair of the guideline writing committee. Early diagnosis and treatment, he explained, not only prevent heart attacks and strokes but also protect long-term brain CHANGES AS THE FIRST TREATMENTFor most Indians, lifestyle is both the problem and the solution. Urban diets high in salt, processed foods, and fried snacks, combined with sedentary jobs and high stress, are fuelling the hypertension guideline reaffirms that healthy lifestyle habits such as cutting down on salt (a major challenge in Indian cooking and packaged foods), eating more fruits, vegetables and whole grains, exercising regularly, maintaining a healthy weight, and managing stress, remain the first line of alcohol, moderation is key. Stress management, whether through yoga, meditation, or simple breathing techniques, has particular resonance in India, where traditional practices can be powerful TOOL FOR PERSONALISED CAREThe new guideline recommends use of the PREVENT risk calculator, which helps doctors estimate an individual's 10- and 30-year risk of heart disease by considering factors like blood pressure, cholesterol, diabetes, and even socioeconomic not yet widely used in India, such tools highlight the importance of tailoring treatment to the person rather than following a one-size-fits-all India, where access to advanced tests is often limited, home blood pressure monitoring can also be a practical and cost-effective way to keep track of health between doctor WHEN NEEDEDWhile lifestyle remains central, medication is often necessary, especially when blood pressure remains high. The guideline suggests starting treatment earlier and, for those with very high readings (140/90 mm Hg or above), using two medicines together for faster used to begin medication mostly when people reached stage 2 hypertension (blood pressure of 140/90 mm Hg or higher). But the new guideline says treatment should start earlier, even at stage 1 hypertension (130–139/80–89 mm Hg), especially if a person has other risks like diabetes, kidney disease, or a family history of heart idea is that bringing blood pressure under control sooner, with lifestyle changes and medicines when needed, can prevent serious complications like heart attack, stroke, and dementia later in blood pressure: less than 120/80 mm Hg. This is where you want to blood pressure: between 120–129 (top number) and less than 80 (bottom number). This is a warning zone — not yet high blood pressure, but a signal to make lifestyle 1 hypertension: between 130–139 (top number) or 80–89 (bottom number). At this stage, doctors may recommend lifestyle changes and, if other health risks are present, starting 2 hypertension: 140/90 mm Hg or higher. This is more serious and usually requires medication along with lifestyle changes to bring numbers India, common medications like ACE inhibitors, ARBs, calcium channel blockers and diuretics are widely available and effective. For those with obesity and type 2 diabetes, both rising in the country, newer therapies such as GLP-1 drugs may offer added benefits in the ON WOMEN AND PREGNANCYThe guidelines also highlight high blood pressure in pregnancy, a serious concern in India where maternal health remains a challenge. Conditions like preeclampsia can threaten both mother and child and raise a woman's long-term risk of heart recommend close monitoring of blood pressure during and after pregnancy, timely treatment, and in some cases, low-dose aspirin to reduce risk. Postpartum follow-up is equally crucial, since blood pressure problems can persist or develop after deliveryAs Dr. Jones summed up, 'Prevention, early detection and management of high blood pressure are critical to long-term heart and brain health, which means longer, healthier lives.'advertisementFor India, this advice could not be more timely.- Ends
Time of India
an hour ago
- Time of India
Smoking status must be captured in cancer trials, experts say in new study
New Delhi: A group of experts from AIIMS Delhi, McMaster University in Canada and the International Agency for Research on Cancer (IARC) in France has stressed the need to record smoking status in cancer clinical trials, warning that continued tobacco use can reduce treatment efficacy and patient survival. In a commentary published in the Lancet Oncology this month, the seven authors, including Dr Abhishek Shankar from AIIMS Delhi, said knowledge of smoking status during therapy could influence clinical decisions. They argued that addressing barriers to tobacco-use assessment and embedding smoking cessation initiatives into oncology research protocols will improve trial outcomes, enhance therapeutic efficacy and save lives. The researchers cited the 2014 US Surgeon General's report 'The Health Consequences of Smoking -- 50 Years of Progress', which for the first time concluded there was a causal link between cigarette smoking and adverse cancer-related outcomes, including higher all-cause and cancer-specific mortality. This report underscores the need to systematically capture smoking status in clinical trials, to refine estimates of efficacy of novel therapies and to better understand the impact of continued tobacco use across treatment modalities and disease sites. Since 2014, research has increasingly shown that continued tobacco use negatively impacts patients receiving surgery, radiotherapy or systemic therapies. The mechanisms by which tobacco smoke worsens outcomes remain unclear but may include tumour hypoxia, altered drug metabolism, stimulation of signalling pathways by nicotine and changes to the immune system, including reduced natural killer cells, the authors noted. "Little is known about how best to overcome the effects of tobacco smoke, apart from cessation of tobacco use. Knowledge of smoking status during cancer therapy could potentially influence clinical decisions," the authors said in the commentary. They cited how the dose of erlotinib has to be doubled (from 150 mg to 300 mg daily) to achieve therapeutic concentrations in patients who continue smoking. "These findings highlight a large gap in our understanding of how continued tobacco use might influence drug metabolism, therapeutic response and long-term outcomes," the experts said, adding that the issue is most pressing in low and middle-income countries with 80 per cent of tobacco users. Meta-analyses of lung, head and neck, hormone-responsive and other cancers show that quitting smoking after diagnosis results in longer survival, with early quitting offering the greatest benefits. The authors stressed that the survival advantage of quitting could even exceed the impact of the therapy under investigation. They also cautioned that failure to collect smoking data risks confounding trial results, especially if treatment groups are unbalanced for tobacco use. The commentary pointed out that the 2020 US Surgeon General's report recommended structured cessation efforts as standard cancer care, though it said more data was needed to confirm a causal link with improved survival. The authors referred to a 2020 US FDA-AACR-IASLC workshop which addressed the importance of tobacco-use assessment in oncology trials. Despite such efforts and published evidence, clinical trials still rarely incorporate robust tobacco-use assessments, they said. Absence of standardised tools and protocols for assessing tobacco use leads to inconsistencies in data collection, making it challenging to compare results across studies, authors added. They further said that some researchers and clinicians might perceive tobacco use as having minimal impact on clinical outcomes, leading to its omission from data collection. "However, evidence strongly suggests that continued tobacco use can have a substantial adverse effect on cancer treatment efficacy and patient survival," the authors said. They also said that opportunities to intervene with current users after diagnosis have been missed, and more research is needed on mechanisms by which tobacco worsens outcomes. Collecting detailed smoking data requires time and resources, which might be limited in clinical trial settings, they pointed out. Electronic health record systems might not have integrated templates for recording smoking status information, leading to inconsistent documentation. The absence of automated prompts or referral systems can further impede the collection of accurate tobacco use data, the doctors said, adding that pharmaceutical manufacturers might perceive smoking status assessments as a threat. If smoking diminishes a drug's efficacy or exacerbates side-effects, it could negatively impact regulatory approval and market size, they added. Referring to a 2024 study by Cincirpini and colleagues, they said cessation support should ideally be provided within six months of diagnosis to observe the greatest survival benefit. With e-cigarette use rising globally, their use should also be captured in trials, though their impact is likely to be less severe than active smoking. In the past decade, many cancer centres in Canada, Australia and the US have made smoking cessation discussions standard practice at the time of patient registration, with advice and referrals offered. In 2023, the IASLC's Tobacco Control and Smoking Cessation Committee also issued a position statement declaring smoking status capture as a key standard for clinical trial design. "Capturing smoking status in clinical trials should no longer be considered optional; it should be regarded as an essential core element of cancer research," the authors concluded.>
Time of India
3 hours ago
- Time of India
Afghanistan's healthcare system on verge of collapse amid aid cuts, facility closures
Kabul: Afghanistan's healthcare system is on the brink of collapse following the Taliban's takeover, as the international aid which previously supported medical services in the country has been almost cut off, Khaama Press reported. The Khaama Press, citing the US-based New Lines newspaper, reported that more than half of the country's population (around 23 million) needs assistance to access food, clean water, or basic healthcare. The withdrawal of foreign aid and international relief agencies has plunged Afghanistan's healthcare system into a severe crisis, leaving millions without reliable access to medical treatment. According to the World Health Organisation (WHO), over 425 health facilities have been shut down, compelling patients to travel for hours to reach the nearest functioning hospital or clinic, Khaama Press reported. Despite the end of large-scale fighting, hospitals are in a state of emergency. Doctors in Afghanistan are now treating injuries from domestic violence, stabbings, and road accidents, as well as medical complications arising from the lack of primary healthcare, as per Khaama Press. Health experts have cautioned that a swift resurgence of international funding and supplies is crucial to prevent Afghanistan's health system from collapsing entirely, which would result in a significant surge in preventable deaths. Aid organisations are calling for immediate action from the global community, warning that Afghanistan's health crisis is as dire as it was during the war, Khaama Press reported.
